Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

This is a randomized, placebo-controlled, parallel-group, non-confirmatory, investigator and participant blinded study in adult participants with moderate to severe AD.

Key Inclusion Criteria:

• Able and willing to sign the informed consent form
• Patients with a diagnosis of atopic dermatitis and disease for at least 1 year
• Moderate to severe atopic dermatitis

Key Exclusion Criteria:

• Participants with a clinically significant medical condition or infectious disease (as specified in the protocol)
• Participants with any clinically significant abnormal clinical laboratory tests, vital signs, physical examination or ECG
• Participant with any other active inflammatory skin disease would interfere with the appropriate assessment of atopic dermatitis in the opinion of the investigator
• Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
• Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma)
• Women of childbearing potential unless they are using highly effective methods of contraception (failure rate < 1% per year) while taking study treatment.

Other protocol-defined inclusion/exclusion criteria may apply.